Ovid Therapeutics Inc. (OVID) — 8-K Filings

8-K Filings (15)

• 8-K Filing — Dec 18, 2025
• 8-K Filing — Dec 11, 2025
• Ovid Therapeutics Files 8-K on Agreements and Equity Sales — Oct 3, 2025 Risk: medium
  Ovid Therapeutics Inc. filed an 8-K on October 3, 2025, reporting on several events as of October 2, 2025. These include entering into a material definitive agr
• Ovid Therapeutics Files 8-K Current Report — Sep 16, 2025 Risk: low
  Ovid Therapeutics Inc. filed an 8-K on September 16, 2025, reporting an event on September 11, 2025. The filing is a current report under Section 13 or 15(d) of
• Ovid Therapeutics Files 8-K on Security Holder Matters — Jul 10, 2025 Risk: low
  Ovid Therapeutics Inc. filed an 8-K on July 10, 2025, reporting on the submission of matters to a vote of security holders. The filing details events that occur
• Ovid Therapeutics Files 8-K — Jun 25, 2025 Risk: low
  Ovid Therapeutics Inc. filed an 8-K on June 25, 2025, reporting an event under "Other Events." The filing details the company's corporate information, including
• Ovid Therapeutics Files 8-K on Shareholder Nominations — May 2, 2025 Risk: low
  Ovid Therapeutics Inc. filed an 8-K on May 2, 2025, reporting on shareholder nominations pursuant to Exchange Act Rule 14a-11. The filing indicates that the com
• Ovid Therapeutics Announces Executive and Director Appointments — Mar 5, 2025 Risk: low
  Ovid Therapeutics Inc. announced on March 1, 2025, changes in its executive and director roles. Dr. Amit Patel has been appointed as Chief Medical Officer, and
• Ovid Therapeutics Faces Delisting Concerns — Feb 13, 2025 Risk: high
  Ovid Therapeutics Inc. filed an 8-K on February 13, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The earlie
• Ovid Therapeutics Relocates Principal Executive Offices — Sep 11, 2024 Risk: low
  Ovid Therapeutics Inc. announced on September 8, 2024, a change in its principal executive offices to 441 Ninth Avenue, 14th Floor, New York, NY 10001. The comp
• Ovid Therapeutics Appoints New CEO — Aug 2, 2024 Risk: medium
  Ovid Therapeutics Inc. announced on July 30, 2024, a change in its board of directors. Dr. Jeremy Levin has been appointed as the new Chief Executive Officer an
• Ovid Therapeutics Files 8-K — Jul 1, 2024 Risk: low
  Ovid Therapeutics Inc. filed an 8-K on July 1, 2024, to report other events. The filing does not contain specific details about the nature of these events, doll
• Ovid Therapeutics Appoints New CEO, Dr. Amit Patel — Jun 28, 2024 Risk: medium
  Ovid Therapeutics Inc. announced on June 27, 2024, that its Board of Directors has appointed Dr. Amit Patel as Chief Executive Officer, effective immediately. D
• Ovid Therapeutics Files 8-K — Jun 17, 2024 Risk: low
  Ovid Therapeutics Inc. filed an 8-K on June 17, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain
• Ovid Therapeutics Files 8-K on Shareholder Vote — Jun 7, 2024 Risk: low
  Ovid Therapeutics Inc. filed an 8-K on June 7, 2024, reporting on a matter submitted to a vote of security holders on June 6, 2024. The filing details the compa

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX